A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Residual FVIII Levels ≤ 1 IU/dL and Pre-existing Antibodies Against AAV5

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2017
This article has no abstract
Epistemonikos ID: 87e1204cea13733ca5c2ff57ac14918eee548666
First added on: Jan 23, 2025